Menu Back to DIA-Annual-Canadian-Meeting


Short Courses: October 29
Meeting: October 30-31
The DIA Annual Canadian Meeting will deliver a comprehensive overview of the current bio-pharma and device landscape in Canada, while sharing insights into Canada’s broader role in global healthcare product development. From policy updates and priorities shared directly from Health Canada, to sessions on international work sharing to key regulatory and clinical considerations for biologics and biosimilars, you will have the exclusive opportunity to address the current issues and opportunities in Canada and across the globe.

Bringing together key stakeholders from the pharmaceutical and device industries, regulatory agencies, and academia, this meeting will analyze the relevant challenges and opportunities for professionals working in drug and device development in Canada.

This year’s meeting will feature preconference short courses, plenary sessions, multi-track breakout sessions and multiple networking opportunities.

Travel Once, Learn Twice!
This year the DIA Annual Canadian Meeting will be co-located with DIA's Canadian Pharmacovigilance and Risk Management Conference. Maximize your education and time by attending both! Save* $150 when you register for both!
*You must register for both events at the same time.
While we prepare this year's agenda, take a look at our program from 2017 here.

On-Demand Complimentary Webinar

Plain Language Labeling for Over-the-Counter Drugs: Implementing Health Canada’s Guidance for Industry
This webinar will review Health Canada’s requirements for Plain Language Labeling (PLL) for over-the-counter medicines, which just came into force in June 2017. We will walk through key recently finalized and revised guidance documents to help industry comply with these requirements and identify strategies to help industry add Drug Facts Tables to packaging while minimizing the need for packaging increases.

Register today!

Program Committee

  • Karen  Feltmate
    Karen Feltmate President
    Redstone Health Group, Inc., Canada
  • Marc F. Poitras, PhD, MBA
    Marc F. Poitras, PhD, MBA Scientific Manager, Marketed Pharmaceuticals and Medical Devices Bureau
    Health Canada, Canada
  • Marilena  Bassi, MA
    Marilena Bassi, MA Director of the Bureau of Policy
    Health Canada, Canada
  • Lisa  Chartrand
    Lisa Chartrand Director, Regulatory Affairs and Quality Management
    Hoffmann-La Roche Limited, Canada
  • Loretta  Del Bosco
    Loretta Del Bosco Director, Regulatory Affairs Quality Assurance Operations
    AbbVie Corporation, Canada
  • Fiona  Frappier, PhD
    Fiona Frappier, PhD Senior Policy Analyst
    Health Canada, Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Director, Regulatory Affairs; Worldwide Safety and Regulatory-Innovative
    Pfizer Canada Inc, Canada
  • Melissa  Hunt, MSc
    Melissa Hunt, MSc Scientific Manager
    Health Canada, Canada
  • Keith  McIntosh
    Keith McIntosh Executive Director, Scientific & Regulatory Affairs
    Innovative Medicines Canada, Canada
  • Rania  Mouchantaf, PhD
    Rania Mouchantaf, PhD Proactive Pharmacovigilance-Risk Management Planning
    Health Canada, Canada
  • Lissa  Murseli
    Lissa Murseli Manager
    Health Canada, Canada
  • Polina  Ostrovsky, MPH
    Polina Ostrovsky, MPH Policy Analyst
    Health Canada, Canada
  • Kristin  Willemsen, MS
    Kristin Willemsen, MS Director of Scientific & Regulatory Affairs
    Consumer Health Products Canada, Canada
  • Ashley  Zakhem
    Ashley Zakhem Policy Analyst
    Health Canada, Canada
Load More

Contact us

Registration Questions?

Send Email

Co-located Meeting

Canadian Pharmacovigilance and Risk Management Strategies Conference
*Save $150 when you register for both at the same time!

Call for Abstracts

Guidlines | Submit

Submission Deadline: Monday, April 16

Digital Learning Catalog

DIA Learning: 2018 eLearning Soultions